4-(4-Morpholinylmethyl)benzoyl chloride | 123742-32-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-Morpholinylmethyl)benzoyl chloride
• 英文别名: p-morpholinomethylbenzoyl chloride；4-morpholinomethylbenzoyl chloride；α-morpholinoparatoluic acid chloride；4-morpholin-4-ylmethyl-benzoyl chloride；4-(morpholin-4-ylmethyl)benzoyl chloride
• CAS: 123742-32-5
• 化学式: C₁₂H₁₄ClNO₂
• 分子量: 239.702
• InChiKey: BTOCBOHEIFMLMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-Morpholinylmethyl)benzoyl chloride 在 sodium azide 作用下， 以 四氢呋喃 、 水 、 甲苯 为溶剂， 反应 2.0h， 生成 1-(4-(morpholinomethyl)phenyl)-3-(4-((3-(trifluoromethyl)phenyl)amino)quinazolin-6-yl)urea
  参考文献：
  名称：

  Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents

  摘要：

  In present study, 4-anilinoquinazolines scaffold, arylurea and tertiary amine moiety were combined to design, synthesize gefitinib analogs and discover novel anticancer agents. A series of 4-anilinoquinazoline derivatives (1, 2, 3 and 4) bearing arylurea and tertiary amine moiety at its 6-position were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against A431 cell and A549 cell. The SAR of the title compounds was discussed. The compounds 2d, 2i and 2j with potent antiproliferative activities were evaluated their inhibitory activity against EGFR-TK. Compound 2j displayed potent inhibitory activity against EGFR-TK. In addition, compound 2j, at 50 mg/kg, can completely inhibit cancer growth in established nude mouse A549 xenograft model in vivo. These results suggest that the 4-anilinoquinazoline derivatives bearing diarylurea and tertiary amino moiety at its 6-position can serve as anticancer agents and EGFR inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.12.001
• 作为产物：
  描述：

  对甲酰基苯甲酸甲酯 在 氯化亚砜 、 三乙酰氧基硼氢化钠 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.0h， 生成 4-(4-Morpholinylmethyl)benzoyl chloride
  参考文献：
  名称：

  Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents

  摘要：

  In present study, 4-anilinoquinazolines scaffold, arylurea and tertiary amine moiety were combined to design, synthesize gefitinib analogs and discover novel anticancer agents. A series of 4-anilinoquinazoline derivatives (1, 2, 3 and 4) bearing arylurea and tertiary amine moiety at its 6-position were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against A431 cell and A549 cell. The SAR of the title compounds was discussed. The compounds 2d, 2i and 2j with potent antiproliferative activities were evaluated their inhibitory activity against EGFR-TK. Compound 2j displayed potent inhibitory activity against EGFR-TK. In addition, compound 2j, at 50 mg/kg, can completely inhibit cancer growth in established nude mouse A549 xenograft model in vivo. These results suggest that the 4-anilinoquinazoline derivatives bearing diarylurea and tertiary amino moiety at its 6-position can serve as anticancer agents and EGFR inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.12.001

文献信息

• Quaternary bis-ammonium salt precursors and their uses as prodrugs having an antiparasitic activity
  申请人：Vial Henri

  公开号：US06972343B1

  公开（公告）日：2005-12-06

  The invention concerns drug precursors with antimalarial effect, characterised in that it consists in quaternary bis-ammonium salts of general formula (I) wherein A and A′, identical or different, are respectively either a group A1 and A′1 of formula (1) wherein n=2 to 4; R′1 is hydrogen, C1-C5 alkyl, optionally substituted by an aryl, a hydroxy, an alkoxy, wherein the alkyl comprises 1 to 5 C, or aryloxy and W is halogen or a nucleofuge group; or a group A2 which represents formyl-CHO, or acetyl-COCH3. B and B′, identical or different, represent respectively either the group B1 and B′1, if A and A′ respectively represent A1, A′1, B1, B′1 representing a group R1 which has the same definition as R′1 above, but cannot be a hydrogen atom; or respectively the groups B2 and B′2, if A and A′ represent A2, B2 or B′2 being the group R1 as defined above, or a group of formula (2) wherein —Ra is RS— or RCO—, wherein R is a C1-C6 alkyl, substituted if required, a phenyl or benzyl, wherein the phenyl is substituted if required, the latter being optionally substituted; R2 is hydrogen, C1-C5 alkyl, or a —CH2-COO— (C1-C5)alkyl group; and R3 is hydrogen, C1-C5 alkyl or alkenyl, substituted if required, a phosphate, an alkoxy wherein the alkyl is a C1-C3 alkyl, or aryloxy; or an alkyl (or arylcarbonyloxy; or R2 and R3 form together a cycle with 5 or 6 C; R and R3 can be bound to form a cycle. ± represents: either a single bond when A and A′ represent A1 and A′1: or when A and A′ represent A2, and B2 and B′2 Represent (3) either, when A and A′ are —CHO or —COCH3 and B2 and B′2 are R1, a group of formula (4) or a group of formula (5) wherein (a) represents a bond towards Z and (b) a bond towards the nitrogen atom. Z is a C9-C21 alkyl, if required with insertion of one or several bonds, and/or one or several heteroatoms O and/or S and/or several aromatic cycles, and the pharmaceutically acceptable salts of said compounds. Said precursors and cyclized thiazolium derivatives are useful as antiparasitic medicines in particular antimalarial and antibabesiosis.

  该发明涉及具有抗疟疾作用的药物前体，其特征在于它由通式(I)的季铵双盐组成，其中A和A′，相同或不同，分别是通式(1)的A1和A′1基团，其中n=2至4；R′1是氢，C1-C5烷基，可选地被芳基、羟基、烷氧基（其中烷基包括1至5个碳）、芳氧基取代，W是卤素或亲核离去基；或者是代表甲酰基-CHO或乙酰基-COCH3的A2基团。B和B′，相同或不同，分别代表A和A′分别表示A1、A′1、B1、B′1的情况下的B1和B′1基团，其中B1、B′1代表与上述R′1相同定义的R1基团，但不能是氢原子；或者分别代表A和A′表示A2的情况下的B2和B′2基团，其中B2或B′2是如上定义的R1基团，或者是通式(2)的基团，其中-Ra是RS-或RCO-，其中R是C1-C6烷基，必要时取代，苯基或苄基，其中苯基在必要时取代，后者是可选地取代的；R2是氢、C1-C5烷基，或者是—CH2-COO-(C1-C5)烷基；R3是氢、C1-C5烷基或烯烃基，必要时取代，磷酸酯、烷氧基（其中烷基是C1-C3烷基）或芳氧基；或者是烷基（或芳基羰基氧基；或者R2和R3共同形成一个含有5或6个碳的环；R和R3可以结合形成一个环。±表示：当A和A′表示A1和A′1时，是单键；或者当A和A′表示A2，B2和B′2表示(3)时，当A和A′为—CHO或—COCH3，B2和B′2为R1时，是通式(4)的基团或通式(5)的基团，其中(a)表示朝向Z的键，(b)表示朝向氮原子的键。Z是C9-C21烷基，必要时插入一个或多个键，和/或一个或多个杂原子O和/或S，和/或几个芳香环，以及所述化合物的药学上可接受的盐。所述前体和环化噻唑衍生物作为抗寄生虫药物，特别是抗疟疾和抗巴贝斯病的药物是有用的。
• Design, synthesis, and biological activity of 4-(imidazo[1,2- b ]pyridazin-3-yl)-1 H -pyrazol-1-yl-phenylbenzamide derivatives as BCR–ABL kinase inhibitors
  作者：Liming Hu、Tingting Cao、Yongjuan Lv、Yiming Ding、Leifu Yang、Qiang Zhang、Mingzhou Guo

  DOI：10.1016/j.bmcl.2016.10.007

  日期：2016.12

  A series of 4-((pyrazolo[1,5-a]pyrimidin-6-yl)-1H-pyrazol-1-yl)phenyl-3-benzamide derivatives and 4-((imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-)phenyl-3-benzamide derivatives were designed, synthesized as new BCR–ABL tyrosine kinase inhibitors by using combinational strategies of scaffold hopping and conformational constraint. These new compounds were screened for BCR–ABL1 kinase inhibitory activity

  一系列4-（（吡唑并[1,5 - a ]嘧啶-6-基）-1 H-吡唑-1-基）苯基-3-苯甲酰胺衍生物和4-（（咪唑并[1,2- b ]设计了哒嗪-3-基）-1 H-吡唑-1-基-）苯基-3-苯甲酰胺衍生物，采用支架跳跃和构象约束的组合策略合成了新的BCR-ABL酪氨酸激酶抑制剂。筛选了这些新化合物的BCR–ABL1激酶抑制活性，其中大多数对BCR–ABL1激酶均表现出良好的抑制活性。最有效的化合物之一16a强烈抑制BCR-ABL1激酶，IC 50值为8.5 nM。经测试的化合物16a和16i表现出对K562的强抑制活性，IC 50值小于2 nM。分子对接研究表明，这些化合物与BCR–ABL1蛋白的活性位点非常吻合。结果表明，这些抑制剂可能是进一步开发针对BCR-ABL激酶的新药的先导化合物。
• [EN] SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF<br/>[FR] CARBOXAMIDES DE N-PHÉNYL-BIPYRROLIDINE SUBSTITUÉS ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：SANOFI AVENTIS

  公开号：WO2009052065A1

  公开（公告）日：2009-04-23

  The present invention discloses and claims a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I), Wherein R, R1, R2, R3 and R4 are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, this invention also discloses methods of preparation of substituted N-phenyl-bipyrrolidine carboxamides and intermediates therefor.

  本发明公开并声明了一系列式(I)的取代N-苯基-双吡咯烷羧酰胺，其中R、R1、R2、R3和R4如本文所述。更具体地说，本发明的化合物是H3受体调节剂，因此在制药方面特别有用，尤其是在治疗和/或预防通过H3受体调节的各种疾病，包括与中枢神经系统相关的疾病。此外，本发明还公开了取代N-苯基-双吡咯烷羧酰胺及其中间体的制备方法。
• New Acyl Derivatives of 3-Aminofurazanes and Their Antiplasmodial Activities
  作者：Theresa Hermann、Patrick Hochegger、Johanna Dolensky、Werner Seebacher、Robert Saf、Marcel Kaiser、Pascal Mäser、Robert Weis

  DOI：10.3390/ph14050412

  日期：——

  shown activity against different strains of Plasmodium falciparum. Seventeen new derivatives were prepared and tested in vitro for their activities against blood stages of two strains of Plasmodium falciparum. Several structure–activity relationships were revealed. The activity strongly depended on the nature of the acyl moiety. Only benzamides showed promising activity. The substitution pattern of their

  一项针对疟疾的药物风险投资（MMV）项目的N-酰化呋喃3胺已显示出对不同菌株恶性疟原虫的活性。制备了17种新的衍生物，并在体外测试了它们对两株恶性疟原虫血液阶段的活性。揭示了几种构效关系。活性强烈取决于酰基部分的性质。仅苯甲酰胺显示出有希望的活性。它们的苯环的取代方式影响化合物的活性和细胞毒性。另外，通过PAMPA计算（log P，log D，配体效率）或通过实验确定其物理化学参数（渗透率）。该ñ-（4-（3,4-二乙氧基苯基）-1,2,5-恶二唑-3-基）-3-（三氟甲基）苯甲酰胺具有良好的理化性质，对氯喹敏感菌株具有很高的抗血浆活性（IC 50（ NF54）= 0.019 µM）甚至更高的抗多重耐药菌株的抗疟原虫活性（IC 50（K 1）= 0.007 µM）。与MMV化合物相比，提高了通透性和抗多抗性菌株的活性。
• 一种能应用于细胞溶酶体内HOCl检测的罗丹明B类荧光探针
  申请人：泰山医学院

  公开号：CN108774240A

  公开（公告）日：2018-11-09

  本发明公开了一种能够应用于细胞溶酶体内HOCl检测的罗丹明B类荧光探针。该探针以罗丹明B为荧光团，硫代双酰肼为响应基团，并在探针结构中引入吗啉结构作为溶酶体定位基团。在没有HOCl存在时，探针不发荧光；当HOCl存在时，探针在592nm处发出强的荧光。荧光强度随次氯酸浓度的增加而变强，在HOCl浓度为0‑2μM的范围内，荧光强度与次氯酸的浓度成线性增长。该探针具有高选择性，高灵敏度，响应快速的特点，并能应用于细胞溶酶体内HOCl的检测，具有广阔的运用前景。